Nu Skin (NUS) Q2 2026 earnings review
Massive Impairments and Slashed Guidance Expose the Turnaround's Flaws
Nu Skin's strategic transition has collided violently with reality. While Adjusted EPS of $0.20 met expectations, GAAP Net Income collapsed to a staggering $(249.8) million loss, driven by $246 million in non-cash impairment and tax valuation charges. These write-downs are a loud admission that previous growth projections are no longer viable. Revenue fell 17.1% year-over-year to $320.1 million—a sharp deceleration from last quarter's 12% drop—with every single geography and business segment flashing red. Consequently, management slashed its full-year 2026 revenue guidance by $70 million at the midpoint, highlighting severe structural and macroeconomic headwinds.
🐂 Bull Case
Despite top-line decimation, the core Nu Skin business gross margin actually expanded slightly to 77.7% (up from 77.5%), proving that localized manufacturing and Project Accelerate cost controls are working.
The massive impairment and tax allowance charges are non-cash. By taking the hit now, management resets the baseline, lowering the bar for future quarters once Prysm iO and India scale.
🐻 Bear Case
You cannot grow a multi-level marketing business without sellers and buyers. Customers are down 14%, Paid Affiliates fell 8%, and Sales Leaders dropped 9% year-over-year. The ecosystem is bleeding.
Rhyz Manufacturing, intended to be a diversification and growth engine, saw revenue plummet 23.2% year-over-year. The turnaround story relies heavily on Rhyz, but the numbers show rapid deterioration.
⚖️ Verdict: 🔴🔴
Strongly Bearish. A turnaround requires a floor, and Nu Skin has not found it. A $167.5 million tax valuation allowance signals deep pessimism about future profitability, contradicting the positive commentary regarding new platforms.
Key Themes
Massive Paper Write-Downs Contradict Bullish Narrative
The defining feature of Q2 was $246.3 million in paper losses: a $78.9 million asset impairment and a $167.5 million valuation allowance on deferred tax assets. A tax valuation allowance is recorded when a company determines it is 'more likely than not' that it will not generate enough future taxable income to realize those tax benefits. This directly contradicts management's claims of an impending return to growth, signaling internal capitulation on near-term profitability forecasts.
Broad-Based Collapse Led by South Korea and Rhyz
Revenue declined double-digits in seven of eight reporting segments. South Korea is severely lagging, decelerating to a 24.8% YoY drop (vs -21.4% in 26Q1). Rhyz Manufacturing, historically touted as an agile growth engine, reversed its trajectory entirely, plunging 23.2% YoY. The lack of a single regional bright spot highlights the severity of Nu Skin's demand problem.
Macro Headwinds Crushing Consumer Durability
Global economic conditions—including inflation and shifting consumer sentiment—are weighing heavily on discretionary wellness spending. Management's strategic transition involves 'switching costs' for the sales force, but the sheer 14% drop in global customers suggests the macroeconomic environment is exacerbating the friction of this transition, causing an accelerating bleed rather than a controlled pivot.
Prysm iO Ecosystem Adoption
Prysm iO, the AI-powered intelligent wellness platform, remains the company's primary product innovation lever. Management claims it acts as a customer acquisition tool driving higher-lifetime-value subscriptions. Despite the horrific top-line results, this shift from social selling to consultative selling via biometric scanning is the solitary engine for long-term average order value (AOV) improvement.
Core Margin Defense Mechanics
In a quarter with a 17% revenue collapse, the core Nu Skin gross margin was remarkably stable, ticking up from 77.5% to 77.7%. This indicates that the 'Project Accelerate' localized manufacturing strategies and strict cost-of-goods controls are holding the line, ensuring that if volumes ever return, operating leverage will be highly potent.
India Market Entry Pipeline
Nu Skin continues its pre-market strategy for India, targeting a formal launch in late 2026. Leveraging localized 'masstige' products and a digital-first infrastructure built with Infosys, India represents a vital, untapped 1.4-billion-person market essential to offsetting the permanent structural declines occurring in mature markets like North America and South Korea.
Other KPIs
Reversing violently from $30.8 million in the prior-year quarter. Adjusted operating margin of 6.1% stripped out the $78.9 million impairment, but the GAAP numbers reflect the true cost of restructuring the enterprise.
Stable sequentially, but slightly up from 33.2% a year ago. For the core Nu Skin business, selling expenses improved slightly to 39.8% from 40.0%. However, managing this line item cannot offset the sheer lack of gross dollar throughput.
Combined Cash and Current Investments decreased from $239.8 million at the end of FY25. The company authorized no stock repurchases during the quarter, likely preserving liquidity amid severe operational pressure.
Guidance
Decelerating. Management slashed the previous guidance of $1.35-$1.50 billion. The new midpoint ($1.315B) implies a severe 11.4% YoY decline from FY25's $1.485 billion, removing any hope that the second half of 2026 will bring the company back to growth.
Decelerating. Cut aggressively from the prior $0.80 - $1.20 range. GAAP EPS is expected to be deeply negative ($(4.90) to $(4.73)), highlighting that the 'one-time' charges of Q2 will define the full-year profitability profile.
Decelerating. The midpoint of $325 million represents an implied 10.8% YoY drop compared to Q3 2025 ($364.2M). Management anticipates a massive 2% to 3% FX headwind.
Decelerating significantly from the $0.34 delivered in Q3 2025, proving that cost controls have reached their limit against plunging sales volumes.
Key Questions
Tax Valuation Allowance Logic
The $167.5M tax valuation allowance indicates a lack of confidence in generating future taxable income. Which specific geographic markets triggered this write-down, and does this mean you expect sustained unprofitability in those regions?
Prysm iO Adoption Drag
Total customers declined by 14% this quarter. Are the 'switching costs' associated with moving the sales force to the Prysm iO consultative model actively alienating your legacy, transaction-based customer base?
Rhyz Manufacturing Weakness
Rhyz Manufacturing went from being a double-digit growth engine last year to declining 23% this quarter. Is this drop due to lost third-party contracts, or an internal reduction in Nu Skin inventory purchasing?
India Entry Viability
With full-year guidance slashed and liquidity becoming tighter, is the capital required for the late-2026 formal India launch fully ring-fenced, or is that timeline at risk of being pushed back?